Merz looks to invest in early-stage aesthetics

11 June 2015 - Deborah Wilkes


Merz Pharma plans to invest up to €25 million (US$28 million) of corporate venture capital in the aesthetics market. The privately-held company has also just arranged a syndicated loan of up to €500 million, giving it "the greatest possible freedom going forward".

Click tags below for more information on topics:


Annual Subscription Holder?

Sign in to continue reading.

Sign In

Back to Industry News

Share this page: